The board comprises one Executive Director and four Non-Executive Directors.

Chris Spencer.png

Chris Spencer

Non-Executive Chairman Chris has nearly 40 years’ experience in software, healthcare, and...
Chris Spencer.png

Chris Spencer

Non-Executive Chairman

Chris has nearly 40 years’ experience in software, healthcare, and legal matters. He joined EMIS Group plc in 1999 holding senior roles including Chief Administrative Officer and, from 2013, Chief Executive Officer. Currently he serves on a number of digital health related private company boards and is a Digital Health Venture Partner for GM&C Life Sciences Fund at Catapult Ventures Group.

Chris is a solicitor (non-practising). Formerly an Associate of the Chartered Institute of Patent Agents and member of the Law Society of England and Wales and Fellow of the Chartered Management Institute he remains a member of the Society for Computers and Law. He holds an LLB (Hons) and qualified as a solicitor (with distinction).

Hugo Stephenson.png

Hugo Stephenson

Non-Executive Director Hugo has founded several healthcare and biotech services businesse...
Hugo Stephenson.png

Hugo Stephenson

Non-Executive Director

Hugo has founded several healthcare and biotech services businesses including DrugDev (acquired by IQVIA)  MediGuard (owned by IQVIA), Health Research Solutions (acquired by Quintiles, now IQVIA), and MedSeed (acquired by eHealthcare Asia).

Hugo served as full-time Executive Chairman, Product Lead and co-founder at DrugDev from 2012-2017.  Previously, Hugo served as Vice President at Quintiles (now IQVIA) from 2002 to 2011.

Ibs Mahmood.png

Ibs Mahmood

Chief Executive Officer Ibs has a broad background in healthcare, technology and finance h...
Ibs Mahmood.png

Ibs Mahmood

Chief Executive Officer

Ibs has a broad background in healthcare, technology and finance having read Medicine at Oxford, worked as a Healthcare Strategy Consultant at Accenture, Healthcare Investment Banker at Nomura, Lifesciences Equity Research Analyst at Investec and Corporate Venture Capitalist at Shire Pharmaceuticals.

Most recently, Ibs was President and CEO of DrugDev - a leading clinical trial technology company. Between 2011 and 2018 Ibs oversaw the growth of the company from just three people to approximately a thousand with the concomitant growth in the order book of sold business from zero to several hundred million dollars. He also led funding rounds of well over $50m and the sale of the business to IQVIA - the largest clinical research organisation in the world where he worked until late 2018 running their Global Clinical technology business. He also worked as an Entrepreneur-in-Residence for Oxford University’s affiliated $1bn technology transfer fund.

Jane Silber.png

Jane Silber

Non-Executive Director Jane is Executive Chair of Diffblue Ltd and a non-executive direct...
Jane Silber.png

Jane Silber

Non-Executive Director

Jane is Executive Chair of Diffblue Ltd and a non-executive director of The Sensible Code Company Limited. She also serves as an advisor for tech start-ups.

Previously she was CEO of Canonical for 7 years, which followed a 7 year period as COO of Canonical.  With experience in the US, Japan and the UK, she has spent her entire career in software engineering and IT management, starting as a software developer and rising through various leadership roles. She holds a BS from Haverford College, an MS from Vanderbilt University, and an MBA from Oxford University.

Lisa Ann Reed.jpg

Leslie-Ann Reed

Non-Executive Director Leslie-Ann is a chartered accountant with a diverse background and...
Lisa Ann Reed.jpg

Leslie-Ann Reed

Non-Executive Director

Leslie-Ann is a chartered accountant with a diverse background and extensive international experience, having served in both executive and non-executive roles in publicly listed media and professional services companies.

Leslie-Ann is currently Non-Executive Director and Chair of the Audit Committee for Learning Technologies Group plc and Non-Executive Director at Bloomsbury Publishing plc, where she is a member of the Audit and Remuneration Committees. Previously, Leslie-Ann was a Non-Executive Director of the German listed company ZEAL Networks SE where she was Vice Chair of the Supervisory Board and Chaired the Audit Committee. Until May 2018 she was a Non-Executive Director and Chair of the Audit Committee of the London listed publisher Quarto Group, Inc.

From 2010 to 2012 she was Chief Financial Officer of Go Industry Dove Bid plc, leading its successful sale in 2012. Between 2007 and 2010 Leslie-Ann was an adviser to Marwyn Investment Management. Prior to that, she served as Chief Financial Officer of Metal Bulletin plc. Leslie-Ann also held senior finance leadership roles at Universal Pictures, Polygram Music, EMI Music and Warner Communications Inc.